Report : North America Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By State of Finished Product (Solids, Semi-solids, and Liquids), Content (Organic Substances Isolated from Animal Origin, Organic Substances Isolated from Microorganisms, and Inorganic Substances)
Liquid Segment has the Largest Share of State of Finished Products in the North America Pharmaceutical Fill and Finish Outsourcing Market during 2021–2028
According to our latest study on “North America Pharmaceutical Fill and Finish Outsourcing Market Forecast to 2028 – COVID-19 Impact and Analysis – by State of Finished Products, and Content,” the market is projected to reach US$ 1,741.0 million by 2028 from US$ 1,188.8 million in 2021; it is expected to grow at a CAGR of 5.6% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increase in demand for biopharmaceutical drugs, growing clinical developments, and development of biologics and biosimilars. However, complex processes and high cost of production critically impacts the growth of the market.
The outbreak of COVID-19 pandemic in China affected significantly the supply of finished drugs and APIs to the US. For records, an estimated 83% of Chinese import lines to the US were human finished dosage forms, while 7.5% were APIs in 2018. Also, factory lockdowns in China and logistics delays due to coronavirus measures at ports would mean lower production and delays in shipping of APIs to US manufacturers. With the coronavirus spreading, the US based pharmaceutical companies faced cost escalation. Therefore, demand for CMOs along with pharmaceutical companies in North America region was high and is contemplating to get approval for the clinical trial vaccines to prevent COVID-19 infection.
Based on state of finished products, the liquid segment is expected to register the largest market share during the forecast period. Moreover, the same segment is estimated to register the highest CAGR during the forecast period. In 2021, the liquid segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 6.0% in the forecast period.
Abbott, TEVA PHARMACEUTICAL INDUSTRIES LTD, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd., MabPlex International Ltd, WOCKHARDT, Cytovance Biologics, Thermo Fisher Scientific Inc. (Patheon N.V), and Boehringer Ingelheim International GmbH are among the leading companies in the North America pharmaceutical fill and finish outsourcing market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market.
The market for pharmaceutical fill and finish outsourcing market is segmented into state of finished products and content. Based on state of finished products, the North America pharmaceutical fill and finish outsourcing market is segmented into solids, semi-liquid and liquid. Based on content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. Geographically, the pharmaceutical fill and finish outsourcing market is segmented into North America (US, Canada, Mexico).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com